Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Scientists from the Oxford Parkinson’s Disease Centre (OPDC) and the Edinburgh Prion Unit have developed a new diagnostic test for Parkinson’s disease. The test measures the 'stickiness' of a particular protein in the cerebrospinal fluid.

Positive RT-QuIC signal is only detected in the CSF of patients with pathologically confirmed alpha-synucleinopathy. ThT=thioflavine T; RFU= relative fluorescence unit

This protein, known as alpha-synuclein, forms sticky clumps known as Lewy bodies within the brain cells of patients with Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). There is currently no definitive test that allows doctors to determine if someone has Parkinson's or related disorders, especially at the early stage. So at present the diagnosis is based purely on clinical symptoms and can only be confirmed with a post-mortem examination of the brain. 

These are hugely promising results and we are extending the analysis to a larger cohort of OPDC Discovery samples. We are particularly keen to understand how early these changes can be detected and whether our assay could be used as a predictive test. We also hope to refine our technique to detect alpha-synuclein aggregation in the nasal mucosa collected through a safer and less invasive brushing procedure compared to lumbar puncture required for the CSF collection.

- Laura Parkkinen

Previous efforts to develop a test for alpha-synuclein have produced inconsistent results because the protein is also found in the brain and cerebrospinal fluid (CSF) of healthy subjects. It is only when the protein clumps together that it causes problems. 

An extremely sensitive technology called real-time quaking-induced conversion (RT-QuIC) allows the measurement of stickiness of proteins; this approach has already been used to detect the CSF prion protein in Creutzfeldt-Jakob disease. Dr Laura Parkkinen and her team used this technology in brain material derived from the Oxford Brain Bank and CSF samples from the OPDC Discovery cohort. They were able to detect 'sticky' alpha-synuclein protein in the patients with PD and DLB with sensitivities of 95% and 92%, respectively, and with an overall specificity of 100% when compared to Alzheimer’s and controls.

Interestingly, few patients known to be at risk of developing PD/DLB (i.e. patients with REM sleep behaviour disorder) had a positive result. This suggests that this test could potentially detect patients before their motor and/or cognitive symptoms appear and thus allow the initiation of early treatment that could slow or even stop the disease.

Similar stories

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

Director of MRC Brain Network Dynamics Unit appointed

From 2 January 2023, Professor Peter Magill will lead the Medical Research Council Brain Network Dynamics Unit (MRC BNDU) at the University of Oxford.

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Visit from the Sir Jules Thorn Charitable Trust

Earlier this month, we were delighted to welcome the Director of the Sir Jules Thorn Charitable Trust, Richard Benson, and its Chair of Trustees, Liz Charal.